TCL Archive FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says. By Cancer History Project April 1, 2005
TCL Archive ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma. By Cancer History Project December 10, 2004
TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. By Cancer History Project July 30, 2004
TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. By Cancer History Project May 28, 2004
TCL Archive Letters to the Editor: Us Too! Objects to ODAC Member’s Comments; Brawley Responds By Cancer History Project March 28, 2003
TCL Archive ODAC Reviews Post-Marketing Studies for Eight Indications By Cancer History Project March 21, 2003
TCL Archive ODAC Reviews Post-Marketing Studies for Eight Indications By Cancer History Project February 21, 2003
ArticleSpotlight Article A Vote for Cancer: Tobacco Advertising and Presidential Elections By The Center for the Study of Tobacco and Society